Docusate

The reviewed capsules, oral liquid and mini-enema are OTC stool-softener laxatives for occasional constipation. They are marketed under OTC monograph M007; that status is distinct from an individually approved new-drug application. A package listing alone does not establish comparative clinical superiority.

Selected oral products generally act within 12–72 hours; the reviewed rectal mini-enema within 2–15 minutes. Docusate is not an immediate oral rescue medicine. Persistent symptoms or need beyond 1 week warrants assessment instead of treating presumed chronic constipation indefinitely. No bowel-preparation or fecal-impaction regimen is inferred from these labels.

Take by mouth, as one daily dose or divided doses. The table applies to this Colace 100 mg product; it is not a direction for 50 mg capsules, docusate calcium or senna combinations. Swallow capsules whole with water; do not split, chew or crush.

Concentration is 10 mg/mL. Give ONCE daily using a calibrated oral device. The selected PAI label directs taking it with 6–8 fluid ounces of milk, juice or infant formula to mask bitterness. Generic MedlinePlus suggests a different mixing volume; retain this exact product’s directions, and obtain clinician advice if a child cannot take the prescribed fluid volume. Do not substitute another manufacturer’s 300 mg adult liquid maximum.

For adults and children age 12 and older, with adult supervision for children, use 1–3 units daily as labeled; each delivered dose contains 283 mg docusate sodium. Under 12: consult a doctor. This product is RECTAL only and is not swallowed or converted to an oral milligram regimen. Remove the tip, lubricate, insert gently according to package instructions, squeeze and keep squeezed during withdrawal; discard after use. Stop if bleeding or injury is suspected.

Do not continue self-treatment beyond 1 week without clinician direction. The reviewed labels provide no validated CrCl/eGFR-based or hepatic-adjustment formula and no dialysis regimen. Evaluate the underlying cause, dehydration/poor intake and comorbid illness rather than invent a numerical reduction.

The oral products say not to use with current mineral-oil treatment unless a doctor directs it; the mini-enema carries the same interaction precaution and says not to use laxatives with abdominal pain, nausea/vomiting or beyond 1 week unless directed. These OTC Drug Facts are not a prescription-style comprehensive contraindications table. Assess ingredient allergy and concerning bowel symptoms before treatment.

The reviewed OTC Drug Facts labels have no boxed warning. Their red-flag symptom, mineral-oil and duration restrictions still apply; no safety conclusion is inferred for every docusate combination or route.

Possible effects include cramping, nausea and throat irritation from oral liquid. Rash/hives, breathing or swallowing difficulty, severe abdominal symptoms or vomiting require prompt assessment; breathing difficulty needs emergency care. Rectal bleeding or no stool after use should not be dismissed as an expected laxative effect. Product labels do not establish precise event rates.

Do not combine the selected products with mineral oil unless specifically directed by a doctor. This interaction is explicitly labeled; the reviewed Drug Facts do not supply a safe separation interval that makes unsupervised combined use acceptable.

Some products contain docusate plus sennosides; their stimulant component and directions must be assessed separately. Disclose all prescription, OTC and supplement use, and check for duplicate stool-softener/laxative ingredients before adding treatment. A single-ingredient docusate dose is not a combination-product instruction.

Use the exact age limits above: the selected capsule starts doctor-directed review under 2, liquid under 3 and mini-enema under 12. No universal infant dose is supplied. Older adults use the product’s adult directions but need assessment of persistent symptoms, other medicines and ability to measure/administer the product safely; the labels do not define a geriatric adjustment.

The reviewed OTC labels advise asking a health professional before use during pregnancy or breastfeeding. They do not establish comparative pregnancy safety, breastmilk exposure or a universal chronic regimen. Discuss the cause of constipation, intended route, duration and other laxatives with the treating clinician.

The selected labels do not quantify organ-impairment pharmacokinetics. Individual assessment remains necessary. Colace 100 mg contains 5 mg sodium per capsule; selected PAI liquid 14 mg sodium per 5 mL. The liquid contains sorbitol and other excipients even though its package says sugar-free/alcohol-free. Verify the actual ingredients for allergy and dietary restrictions.

Stool softeners make stool easier to pass by softening it. The reviewed oral labels state a 12–72-hour bowel response, while the rectal product acts locally with a 2–15-minute labeled response. Those differences do not support assuming oral and rectal milligram equivalence or guaranteed response in obstructive disease.

No numerical bioavailability, protein binding, half-life or renal-clearance data are supplied in the selected OTC labels. No unsupported systemic-absorption percentage or PK-derived kidney/liver dose is presented. The labeled time to bowel movement describes response, not an elimination half-life.

Assess duration, bowel-habit changes, abdominal symptoms, bleeding and other constipation medicines before use. Track stool response and the daily amount; seek review for no bowel movement after treatment or continued need beyond 1 week. The selected labels do not mandate universal laboratory testing for every brief OTC course.

Confirm concentration/route and measure liquid with a calibrated device. Keep mini-enemas separate from oral medicines, follow lubrication/insertion instructions and discard the unit after use. Swallow capsules whole. Do not increase or double doses to force an immediate oral response; ask a pharmacist if the formulation or instructions are unclear.

Get medical assessment for bleeding, severe pain, persistent vomiting or lack of bowel response. Suspected overdose or accidental enema ingestion requires immediate medical advice. Keep all products away from children; the reviewed liquid unit-dose cups are specifically labeled not child-resistant.

Colace 100 mg oral capsules are packaged by Atlantis Consumer Healthcare; an example 100-capsule bottle is NDC 67618-101-01. Selected PAI cherry liquid is clear pink to purple-pink, 50 mg/5 mL; 473 mL bottle NDC 0121-0935-16. Selected Major mini-enema is 283 mg per delivered rectal dose, item NDC 0904-6920. Confirm actual packaging; appearance alone is insufficient.

Reviewed products are 100 mg oral sodium capsules, 50 mg/5 mL oral sodium liquid and 283 mg-per-delivered-dose rectal mini-enemas. Other strengths, calcium-salt products and docusate/senna combinations require their own verified label. The mini-enema’s nominal 5 mL product information does not authorize substituting an oral 5 mL liquid dose.

Colace specifies 25°C with 15–30°C excursions, tightly closed. Selected PAI liquid 20–25°C, protected from light/freezing; unit cups are not child-resistant. Selected mini-enema 15–30°C and single use. Retain the original package/Drug Facts and follow its tamper-seal instructions.